Phase 1/2a Data Presented On Sept 22, 2021 Onconova presented data at the 3rd Annual RAS Targeted Drug Development Summit from its Phase 1/2a trial in non-small cell lung cancer (NSCLC). Afterward, the company held a conference call in which the Principle Investigator presented the preclinical data, Phase 1/2a trial data, and answered questions.Lead Trial Investigator Presented Data The preclinical data discussion reviewed rigosertib’s mechanism of action and pathways. This included a discussion of how the KRAS mutations lead to loss of control over the cell proliferation process, rigosertib animal models, and data in combination with checkpoint inhibitors.Study Design Has Dose Escalation and then Dose Expansion The Phase 1/2a study enrolled non-small cell lung cancer patients with mutations in the KRAS signaling pathway (KRAS+). The first phase was a dose-escalation to demonstrate safety and tolerability. Next, a dose expansion phase enrolled 12 patients to demonstrate overall response rate and survival. All had failed at least one treatment with a checkpoint inhibitor, six had failed two treatments, and three failed three of more treatments.Patient Evaluation Is Continuing Out of the 12 patients, 7 were evaluable for the data presentation. There were 2 patients with partial responses and with one stable disease. Three patients dropped out before reaching first evaluation due to toxicity. One of the patients with a partial response is alive and continuing treatment, while 2 others have been recently enrolled and have not yet reached the 8-week evaluation point.Conclusion: The data shows that rigosertib can improve survival in patients that have failed the current standard of care. As the rigosertib trial continues to treat and enroll additional cohorts, the two Phase 1 trials for ON 123300 in solid tumors are continuing. We reiterate our Outperform rating and price target of $11 per share. Read More >>